Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | POLM | Q9NP87 | 1/20 | 0.48 |
| ▸ | POLK | Q9UBT6 | 1/20 | 0.48 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.48 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.45 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7209562 | 0.98 | MEN1 (0.61) | MEN1KMT2AKDM4ERECQLTSHR | |
| SCHEMBL5706016 | 0.96 | KDM4E (0.63) | MEN1KMT2AKDM4ERECQLTSHR | |
| SCHEMBL8499422 | 0.95 | MEN1 (0.61) | MEN1KMT2AKDM4ERECQLTSHR | |
| SCHEMBL8498851 | 0.92 | TSHR (0.65) | MEN1KMT2AKDM4ERECQLTSHR | |
| SCHEMBL14723637 | 0.91 | KDM4E (0.51) | MEN1KMT2AKDM4ERECQLTSHR | |
| SCHEMBL13425197 | 0.91 | HDAC1 (0.54) | MEN1KMT2AKDM4ERECQLTSHR | |
| SCHEMBL7351148 | 0.89 | KDM4E (0.56) | MEN1KMT2AKDM4ERECQLTSHR | |
| SCHEMBL7360282 | 0.88 | KDM4E (0.57) | MEN1KMT2AKDM4ERECQLTSHR | |
| SCHEMBL8500487 | 0.88 | KDM4E (0.53) | MEN1KMT2AKDM4ERECQLTSHR | |
| SCHEMBL8587612 | 0.86 | TSHR (0.65) | MEN1KMT2AKDM4ERECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250140406-A1 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | INSIGHT MOLECULAR DIAGNOSTICS INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20250049780-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-02 | — | — | US | disclosed |
| WO-2025006568-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-12070455-B2 | Thienopyrrole compounds | GILEAD SCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| WO-2022140325-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-6180669-B1 | ADMINISTERING A ESTER | TAMARKIN PHARMACEUTICAL INNOVATION LTD. (IL) | 2001-01-30 | — | — | US | disclosed |
| EP-0946485-A4 | METHOD FOR TREATMENT OF DERMATOLOGICAL DISORDERS | TAMARKIN PHARMACEUTICAL INNOVA (IL) | 2000-01-19 | — | — | EP | disclosed |
| EP-0764673-B1 | Process for the production of polycarbonate | TEIJIN LTD (JP) | 1999-11-17 | — | — | EP | disclosed |
| EP-0946485-A2 | METHOD FOR TREATMENT OF DERMATOLOGICAL DISORDERS | Tamarkin Pharmaceutical Innovation Ltd. (IL) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998020834-A2 | METHOD FOR TREATMENT OF DERMATOLOGICAL DISORDERS | TAMARKIN PHARMACEUTICAL INNOVATION LTD (IL) | 1998-05-22 | — | — | WO | disclosed |
| US-5696222-A | MELT POLYCONDENSATION OF AN AROMATIC DIHYDROXY COMPOUND AND DIPHENYLCARBONATE, THEN ADDING A SPECIFIC CARBONATE OR CARBOCYCLIC ESTER TO FORM TERMINAL BLOCKED POLYCARBONATE | TEIJIN LIMITED (JP) | 1997-12-09 | — | — | US | disclosed |
| EP-0764673-A2 | Process for the production of polycarbonate | TEIJIN LIMITED (JP) | 1997-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049780-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | MEN1 2342/4885KMT2A 2746/4885KDM4E 1774/4885 |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | SSB, IDO1, IDO2 | MEN1 2610/4885KMT2A 2152/4885KDM4E 960/4885 |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DUSP2, MKNK2, DUSP22 | MEN1 1999/4885KMT2A 506/4885KDM4E 1575/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | MEN1 1488/4885KMT2A 2952/4885KDM4E 3249/4885 |
| US-12070455-B2 | Thienopyrrole compounds | SSB, TPMT, LCP2 | MEN1 2342/4885KMT2A 2746/4885KDM4E 1774/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | MEN1 1327/4885KMT2A 2890/4885KDM4E 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.